2011-03-08-世界卫生组织-INN_Recommended_List_65_50页_478kb

报告摘要

Summary of WHO Recommended INNs: List 65, 2011

This document recommends 65 new International Nonproprietary Names (INNs) for pharmaceutical substances, as published in WHO Drug Information, Vol. 25, No. 1, 2011. The inclusion of these names does not imply any recommendation for the use of the substances in medicine or pharmacy.

Key points from the recommendations:

The INNs are selected through a specific procedure by the World Health Organization.
Each INN includes the name in Latin, English, French, and Spanish, along with chemical names, molecular formulas, and structural formulas where applicable.
The list covers a range of compounds, including new drugs and modified structures, such as amuvatinibum, anagliptinum, and others detailed in the publication.

Additionally, there are amendments to previous INN lists:

List 6 (for dalanatum insulinum): The description is replaced with one specifying that it is an insulin derivative with the C-terminal alanine removed from the B chain.
List 31 (for suplatastum tosilas): This name is deleted and replaced with "suplatasti tosilas."
List 51 (for ralfinamidum): Changed to priralfinamidum and its chemical name is updated.
List 59 (for sergliflozinum): Revised to "etabonas sergliflozini etabonas."
List 63 (for fonturacetamum): The name is defined with a new chemical structure: rac-2-(4-phenyl-2-oxopiperidin-1-yl)acetamide.
List 64 (for afatinib): The chemical name is corrected to (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-{[(3S)-oxolan-3-yl]oxy}quinazolin-6-yl]-4-(dimethylamino)but-2-enamide.
List 64 (for sotaterceptum): The description is replaced with a fusion protein for immune applications, involving fragments of Homo sapiens ACVR2A and immunoglobulin G1.